← Back to Knowledge Base

Primary topic: PPARG metabolism gene

PPARG Gene and Metabolism: What It Means for Your Body

PPARG influences adipose biology and insulin sensitivity, making it relevant to how energy is stored and how tissues respond to glucose-related signals.

What is the PPARG gene?

PPARG helps regulate adipocyte function and the way the body manages fat storage and insulin sensitivity. It is one of the core genes linking lipid biology with glucose control.

How PPARG affects metabolism

If PPARG-related signaling is less favorable, the body may handle nutrient storage and insulin-related signals less smoothly. That can make appetite, weight, and carb-response questions feel more complicated than generic advice suggests.

What happens when PPARG is altered

Altered PPARG function is usually about changing metabolic tendencies, not a simple yes-or-no problem. The question is whether that tendency shows up in biomarkers and real-world symptoms.

Curated SNP evidence for PPARG

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Lipids

Evidence-backed report connection

PPARG currently has 2 curated SNPs, 6 claim-level scores, and 0 claims eligible for pathway scoring.

Open the sample report
rs1801282Pro12Ala3 claims · 9 study rows

expression · CG

PPARG gene expression

Not used for pathway scoring

rs1801282 CG is associated with reduced PPARG gene expression.

PPARG rs1801282 is scored as a lower PPARG transcriptional-activity tendency for G-containing genotypes, strongest for GG and intermediate for CG.

Likely effectLower gene expression signal
Signal sizeSmall signal
Evidence supportModerate support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1801282 in PPARG and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARG Pro12Ala, with the G allele corresponding to the Ala12 form.PubMed 9806549functional assay · loose proxyDeeb et al. reported that the PPARG2 Ala12 allele had decreased binding affinity to its promoter element and reduced ability to transactivate responsive promoters. This supports lower PPARG-mediated transcriptional activity for G-containing genotypes.PubMed 23065280review · close proxyThe coronary heart disease meta-analysis found no reliable disease association for the 12Ala allele and did not measure PPARG expression or receptor activity. It is retained as context but not scored for the expression claim.

expression · GG

PPARG gene expression

Not used for pathway scoring

rs1801282 GG is associated with reduced PPARG gene expression.

PPARG rs1801282 is scored as a lower PPARG transcriptional-activity tendency for G-containing genotypes, strongest for GG and intermediate for CG.

Likely effectLower gene expression signal
Signal sizeSmall signal
Evidence supportModerate support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1801282 in PPARG and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARG Pro12Ala, with the G allele corresponding to the Ala12 form.PubMed 9806549functional assay · loose proxyDeeb et al. reported that the PPARG2 Ala12 allele had decreased binding affinity to its promoter element and reduced ability to transactivate responsive promoters. This supports lower PPARG-mediated transcriptional activity for G-containing genotypes.PubMed 23065280review · close proxyThe coronary heart disease meta-analysis found no reliable disease association for the 12Ala allele and did not measure PPARG expression or receptor activity. It is retained as context but not scored for the expression claim.

expression · CC

PPARG gene expression

Not used for pathway scoring

rs1801282 CC has no scored directional claim for PPARG gene expression.

PPARG rs1801282 is scored as a lower PPARG transcriptional-activity tendency for G-containing genotypes, strongest for GG and intermediate for CG.

Likely effectNo clear expression signal
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1801282 in PPARG and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARG Pro12Ala, with the G allele corresponding to the Ala12 form.PubMed 9806549functional assay · loose proxyDeeb et al. reported that the PPARG2 Ala12 allele had decreased binding affinity to its promoter element and reduced ability to transactivate responsive promoters. This supports lower PPARG-mediated transcriptional activity for G-containing genotypes.PubMed 23065280review · close proxyA meta-analysis of PPARG Pro12Ala, C161T, and C1431T in coronary heart disease reported contradictory prior case-control results and no significant overall association for the 12Ala allele. This supports keeping the record focused on receptor activity rather than disease prediction.
rs3856806PPARG supporting signal3 claims · 9 study rows

unknown · CC

PPARG unscored target

Not used for pathway scoring

rs3856806 CC has no scored directional claim for PPARG unscored target.

PPARG rs3856806 is scored as unknown and direction-neutral because current evidence does not support a simple general genotype effect.

Likely effectNo clear DNA signal
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs3856806 in PPARG and annotate it as a synonymous coding variant as well as a 3-prime UTR or downstream transcript variant depending on transcript context. This does not by itself establish a clear activity, transport, or biomarker direction.PubMed 25832497review · close proxyA meta-analysis of PPARG rs1801282 and rs3856806 in atherosclerotic diseases reported no overall statistical evidence of significant association, with subgroup findings varying by population and disease type. This supports scoring rs3856806 as unknown and direction-neutral for a general end-user record.PubMed 23065280review · close proxyA separate coronary heart disease meta-analysis found no significant overall association for PPARG Pro12Ala, C161T, or C1431T. Because rs3856806 is commonly discussed as C161T or C1431T, this further supports a conservative neutral score.

unknown · CT

PPARG unscored target

Not used for pathway scoring

rs3856806 CT has no scored directional claim for PPARG unscored target.

PPARG rs3856806 is scored as unknown and direction-neutral because current evidence does not support a simple general genotype effect.

Likely effectNo clear DNA signal
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs3856806 in PPARG and annotate it as a synonymous coding variant as well as a 3-prime UTR or downstream transcript variant depending on transcript context. This does not by itself establish a clear activity, transport, or biomarker direction.PubMed 25832497review · close proxyA meta-analysis of PPARG rs1801282 and rs3856806 in atherosclerotic diseases reported no overall statistical evidence of significant association, with subgroup findings varying by population and disease type. This supports scoring rs3856806 as unknown and direction-neutral for a general end-user record.PubMed 23065280review · close proxyA separate coronary heart disease meta-analysis found no significant overall association for PPARG Pro12Ala, C161T, or C1431T. Because rs3856806 is commonly discussed as C161T or C1431T, this further supports a conservative neutral score.

unknown · TT

PPARG unscored target

Not used for pathway scoring

rs3856806 TT has no scored directional claim for PPARG unscored target.

PPARG rs3856806 is scored as unknown and direction-neutral because current evidence does not support a simple general genotype effect.

Likely effectNo clear DNA signal
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs3856806 in PPARG and annotate it as a synonymous coding variant as well as a 3-prime UTR or downstream transcript variant depending on transcript context. This does not by itself establish a clear activity, transport, or biomarker direction.PubMed 25832497review · close proxyA meta-analysis of PPARG rs1801282 and rs3856806 in atherosclerotic diseases reported no overall statistical evidence of significant association, with subgroup findings varying by population and disease type. This supports scoring rs3856806 as unknown and direction-neutral for a general end-user record.PubMed 23065280review · close proxyA separate coronary heart disease meta-analysis found no significant overall association for PPARG Pro12Ala, C161T, or C1431T. Because rs3856806 is commonly discussed as C161T or C1431T, this further supports a conservative neutral score.

Common symptoms people report

  • weight gain that seems disproportionate to habits
  • slower response to routine nutrition changes
  • signs that glucose tolerance may not be ideal
  • difficulty reconciling appetite, weight, and insulin patterns

Biomarkers to validate

Fasting insulin

Useful for checking whether insulin-related pressure is part of the picture.

Triglycerides

Adds context when lipid storage and glucose handling overlap.

HbA1c

Helpful for longer-term glucose context.

Where DNA analysis helps

DNA can show whether insulin sensitivity and fat-storage pathways are worth prioritizing before using generic diet labels or simplistic body-type explanations.

Example Insight

Your nutrient-partitioning pathway may deserve more attention than standard diet advice suggests.

Suggested validation: fasting insulin and triglycerides.

What to do next

  • Validate fasting insulin and triglycerides before drawing broad conclusions.
  • Look at PPARG together with PPARA, FTO, and IRS1 when weight and glucose issues overlap.
  • Use biomarkers to decide whether the pathway deserves direct attention.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages

PPARA

PPARA fat metabolism gene

IRS1

IRS1 insulin signaling gene

Fasting insulin

fasting insulin and metabolism

Oxidative stress panel

oxidative stress panel and redox load

Glucose regulation pathway

glucose regulation pathway

Caffeine and stimulant sensitivity pathway

caffeine stimulant sensitivity pathway

How accurate are DNA metabolism reports?

how accurate are DNA metabolism reports

Genetic test for weight loss Europe

genetic test for weight loss Europe

Related symptom angle

Why do I gain weight easily genetics

Browse the knowledge base

See the full index of gene guides, biomarker guides, pathway guides, symptoms, buyer pages, and common questions.